Natera (NTRA) reported $367.74 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 52.1%. EPS of -$0.56 for the same period compares to -$1.23 a year ago.The reported revenue represents a surprise of +18.04% over the Zacks Consensus Estimate of $311.54 million. With the consensus EPS estimate being -$0.72, the EPS surprise was +22.22%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Str ...

Exhibit 99.1 Natera Reports First Quarter 2024 Financial Results AUSTIN, Texas, May 9, 2024 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the first quarter ended March 31, 2024. "We had an excellent start to the year, driving robust volume, revenue and margin growth and achieving cash flow breakeven earlier than expected," said Steve Chapman, chief executive officer of Natera. "We continued to deliver on our mission ...

Since inception, Natera (NASDAQ:NTRA) has incurred sustained losses, with their cash burn rate being one of the largest concerns to investors. However, the company seems to be on the verge of becoming profitable for the first time in its history. In my opinion, this is mostly due to the growth of the personalised medicines, particularly in oncology, together with the recently approved biomarkers law in 13 U.S. states. Thus, I consider that Natera as a “buy,” despite the risks associated with it. Personalise ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will participate in the following investor conferences in March. Raymond James 45th Annual Institutional Investors Conference Tuesday, March 5 at 2:15 pm ET | 11:15 am PT in Orlando, FL TD Cowen 44th Annual Health Care Conference Wednesday, March 6 at 9:50 am ET | 6:50 am PT in Boston, MA A live webcast and audio archive of each event may be accessed through the investor rela ...

Natera (NTRA) reported $311.11 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 43.2%. EPS of -$0.64 for the same period compares to -$1.37 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $300.38 million, representing a surprise of +3.57%. The company delivered an EPS surprise of +12.33%, with the consensus EPS estimate being -$0.73.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- ...

Revenue Expectations - The company expects a significant portion of its revenues to be derived from sales of Panorama, Horizon, and Signatera[13] - The company anticipates that Panorama will be adopted for the screening of microdeletions, with third-party payer reimbursement expected to support this testing[13] Financial Performance - The company has incurred net losses since inception and expects to continue incurring losses for the foreseeable future[19] - The company reported an unrealized gain of $13.3 million on available-for-sale securities for the fiscal year ending December 31, 2023[501] Debt and Interest Expenses - The company has $80.4 million gross debt outstanding on its Credit Line as of December 31, 2023, with an interest rate of 30-day SOFR average plus 0.5%[500] - An incremental change in the borrowing rate of 100 basis points would increase the company's annual interest expense by $0.8 million[497] Operational Risks - The company is exposed to foreign currency exchange rate fluctuations as it expands internationally, which may affect its results of operations[502] - The company does not currently believe that inflation has had a material effect on its business, but significant inflationary pressures could harm its financial condition[503] - The company relies on a limited number of suppliers, which may impact its ability to maintain a continued supply of laboratory instruments and materials[22] - The company has experienced rapid growth and may be unable to successfully scale its operations, which could harm its business[22]

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, has met coverage requirements from the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostics Services Program (MolDX) in two new indications: ovarian cancer in the adjuvant and surveillance settings, and breast cancer in the neoadjuvant setting. These determinations add to a growing l ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its fourth quarter and year ended December 31, 2023, after the market close on Feb. 28, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information: Event: Natera’s Fourth Quarter and Year-End 2023 Financial Results Date: Wednesday, Feb. 28, 2024 Time: ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in Gynecologic Oncology validating its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, in endometrial cancer. The full study can be found here. Endometrial cancer (EC) is the most common gynecologic malignancy in the United States. Disease incidence has been rising, but mortality has been rising even faster, potentially due to a highe ...